C-EUBCJupiter Neurosciences
micellar resveratrol, neuroinflammation, oral softgel
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-EUBC
C-EUBCC-EUBCmicellar resveratrol, neuroinflammation, oral softgel
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Honored and excited to share that I've been appointed to the Nugevia Advisory Board at Jupiter Neurosciences, Inc. Nugevia is powered by Jupiter's proprietary JOTROL micellar delivery technology -… | Sanjiv Lal | 36 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can updat
Jupiter Neurosciences Appoints Kristopher Fishman and --> Accessibility: Skip TopNav Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia™ Advisory Board April 07, 2026 08:00 ET | Source: Jupiter Neurosciences, Inc. Jupiter Neurosciences, Inc. New Advisors Bring Nationwide Pharmacy and Wellness Distribution Expertise to Nugevia ™ Consumer Longevity Line Compounding Pharmacy and Wellness Channels Represent Over $1.5 Billion Addressable Market for Practitioner-Grade Nutraceuticals in the U.S. JUPITER, FL, April 07, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Home Skip to main content Home News Sports Opinion Features Delta Business Obituaries eNewspaper Archives Crosswords Comics Newsletters For Subscribers Contributor Content What Ole Miss QB Trinidad Chambliss expects for LSU-Ole Miss matchup Ole Miss quarterback Trinidad Chambliss anticipates a wild atmosphere when Lane Kiffin returns to Oxford with LSU. What to know about Louisiana's closed party primary Senate election Catch up on Miss Louisiana 2026 Who pays for Louisiana data centers' electricity? Governor makes pledge news Who was the Monroe News-Star's girls athlete of the year for 2025-2
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
PHLX Traded|Symbol|Security Name|Listing Exchange|Market Category|ETF|Round Lot Size|Test Issue|Financial Status|CQS Symbol|PSX Symbol|NextShares Y|A|Agilent Technologies, Inc. Common Stock|N| |N|100|N||A|A|N Y|AA|Alcoa Corporation Common Stock |N| |N|100|N||AA|AA|N Y|AAA|Alternative Access First Priority CLO Bond ETF|P| |Y|100|N||AAA|AAA|N Y|AAAA|Amplius Aggressive Asset Allocation ETF|Z| |Y|100|N||AAAA|AAAA|N Y|AAAC|Columbia AAA CLO ETF|P| |Y|100|N||AAAC|AAAC|N Y|AAAD|PGIM AAA CLO Aggregate Duration ETF|P| |Y|100|N||AAAD|AAAD|N Y|AAAP|Pacer Barings CLO Market Flex ETF|Q|G|Y|100|N|N||AAAP|N Y … ion, Inc. - Warrant|Q|S|N|100|N|N||ACONW|N Y|ACP|abrdn Income Credit Strategies Fund Common Shares|N| |N|100|N||ACP|ACP|N Y|ACP$A|abrdn Income Credit Strategies Fund 5.250% Series A Perpetual Preferred Stock|N| |N|100|N||ACPpA|ACP-A|N Y|ACR|ACRES Commercial Realty Corp. Common Stock|N| |N|100|N||ACR|ACR|N Y|ACR$C|ACRES Commercial Realty Corp. 8.625% Fixed-to-Floating Series C Cumulative Redeemable Preferred Stock |N| |N|100|N||ACRpC|ACR-C|N Y|ACR$D|ACRES Commercial Realty Cor … mmon Stock|A| |N|100|N||ACU|ACU|N Y|ACV|Virtus Diversified Income & Convertible Fund Common Shares of Beneficial Interest|N| |N|100|N||ACV|ACV|N Y|ACVA|ACV Auctions Inc. Class A Common Stock|N| |N|100|N||ACVA|ACVA|N Y|ACVF|American Conservative Values ETF|P| |Y|100|N||ACVF|ACVF|N Y|ACVT|Advent Convertible Bond ETF|P| |Y|100|N||ACVT|ACVT|N Y|ACVU|Hartford Alpha Capture Value ETF|Z| |Y|100|N||ACVU|ACVU|N Y|ACWI|iShares MSCI ACWI ETF|Q|G|Y|100|N|N||ACWI|N Y|ACWV|iShares MSCI Glo … sia Dividend Active ETF|P| |Y|100|N||ADVE|ADVE|N Y|ADX|Adams Diversified Equity Fund Inc.|N| |N|100|N||ADX|ADX|N Y|ADXN|Addex Therapeutics Ltd - American Depositary Shares|Q|S|N|100|N|N||ADXN|N Y|AEAQ|Activate Energy Acquisition Corp. - Class A Ordinary Share|Q|G|N|100|N|N||AEAQ|N Y|AEAQU|Activate Energy Acquisition Corp. - Unit|Q|G|N|100|N|N||AEAQU|N Y|AEAQW|Activate Energy Acquisition Corp. - Warrant|Q|G|N|100|N|N||AEAQW|N Y|AEBI|Aebi Schmidt Holding AG - Common Stock|Q|Q|N … ation Common Stock|N| |N|100|N||AEE|AEE|N Y|AEF|abrdn Emerging Markets ex-China Fund, Inc. Common Stock|A| |N|100|N||AEF|AEF|N Y|AEFC|Aegon Funding Company LLC 5.10% Subordinated Notes due 2049|N| |N|100|N||AEFC|AEFC|N Y|AEG|Aegon Ltd. New York Registry Shares|N| |N|100|N||AEG|AEG|N Y|AEHG|Leverage Shares 2X Long AEHR Daily ETF|Z| |Y|100|N||AEHG|
Jupiter Neurosciences updates executive stock options | JUNS 8-K Filing --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks Oi … year Alison Silva prior base salary: $315,000 per year Alison Silva main option grant: 600,000 shares +5 more 8 metrics Alison Silva new base salary $340,200 per year Amended employment agreement as COO and President Alison Silva prior base salary $315,000 per year Before June 5, 2026 amendment Alison Silva main option grant 600,000 shares Options under 2025 Equity Incentive Plan Independent director option grant 100,000 shares each Options for each independent non-employee d … ri bonus options 325,565 options Discretionary bonus in lieu of cash Additional grant to CFO Elmasri 200,000 options One-time grant recognizing contributions Key Terms 2025 Equity Incentive Plan, discretionary bonuses, exercise price, vesting, +1 more 5 terms 2025 Equity Incentive Plan financial "under the Jupiter Neurosciences, Inc. 2025 Equity Incentive Plan (the “Plan”)" discretionary bonuses financial "approved discretionary bonuses to the following executives in the form … t price you agree on today to buy or sell later. vesting financial "Such option grant vests over three years commencing from September 2, 2026 in equal quarterly installments" Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits. independen … eive all the benefits. independent non-employee directors financial "approved a grant of stock options to each of the Company’s independent non-employee directors" See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google Add on Google Not now Understanding 8-K Material Events → Ava
Jupiter Neurosciences, Inc. Secures $2 Million in Direct Offering to Support Parkinson’s Program and Strengthen Balance Sheet | Quiver Quantitative --> Skip to Main Content MEMORIAL DAY API SALE 50% off your first year of Quiver API ... Use Promo Code: MEM50 Quiver API --> × Get a Free Trial on Quiver Premium Today! Upgrade Now Upgrade × Get Email Alerts On JUNS Stock Enter your email to receive free breaking news alerts and insights related to JUNS. Sign Up Now (Free) Home Datasets Most Popular Politician Search Congress Trading 2026 Midterm Elections Donald Trump Stock Trades Ele … et-moving data, filings, and signals for JUNS in real time. Sign Up $JUNS Hedge Fund Activity We have seen 7 institutional investors add shares of $JUNS stock to their portfolio, and 7 decrease their positions in their most recent quarter. Here are some of the largest recent moves: VESTOR CAPITAL, LLC added 970,314 shares (+144607.2%) to their portfolio in Q1 2026, for an estimated $365,032 CITADEL ADVISORS LLC added 101,661 shares (+inf%) to their portfolio in Q1 2026, for a
Demos: UI Controls and Frameworks --> Demos: UI Controls and Frameworks | DevExpress Chat Now Cart My Downloads Free Trial Log In Products Products MULTI-PLATFORM PACKAGES Universal Subscription Our Best Value – includes over 600 UI Controls, our award-winning reporting platform, DevExpress Dashboard, the eXpressApp Framework, CodeRush for Visual Studio and more. DXperience Subscription Save Hundreds – includes DevExpress UI Controls for WinForms, Blazor, ASP.NET Core (MVC & Razor Pages), ASP.NET Web Forms, MVC 5, WPF, our award-winning reporting platform and CodeRush for Visual Studio. HIGHLI … cumentation Code Examples Demos Training Need help or require more information? Submit your support inquiries via the DevExpress Support Center for assistance. Blogs About Us About Us CONNECT WITH DEVEXPRESS Blogs Events, Meetups and Tradeshows LEARN MORE ABOUT DEVEXPRESS About Us Careers / Job Opportunities News User Comments and Case Studies Our Awards MVP Program Announcing DevExpress Universal v26.1 Developer Express Inc is proud to announce the immediate availability of … ad Download DevExpress WinForms demo applications from GitHub. Outlook-Inspired Application Build apps with the UI elements your customers have come to expect from the world's most popular software suite. Run Demo Dental Clinic Application Create a relatively modern UX – a user experience that can be applied to different industries with minimal changes. Run Demo Stock Market Trader Build WinForms applications that replicate the innovative navigation UI. Run Demo New HTML & … S markup. Run Demo Learn more about HTML & CSS Support Touch-Enabled Hybrid Application Build touch-friendly WinForms applications that meet the evolving needs of your enterprise. Run Demo Fluent Mail Client Application In this demo application we use our Fluent Design Form to replicate Microsoft Mail's UI. Run Demo Help Resources Documentation Online Training Examples Tutorial Videos Getting Started with the Grid Control Getting Started with the Ribbon Control Getting St … UI — Case Study by DataWerkes: Field Services Management Platform (TimeWerkes) Application Security — Documents Are Untrusted Input Application Security — Stronger Hashes and Safer Passwords WPF Demos With over 130 optimized UI controls and libraries, the DevExpress WPF Subscription , can help you create powerful and visually stunning business s
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering | Markets Insider Business Insider My Markets Watchlist Markets News Search Business Strategy Economy Finance Retail Advertising Careers Law Media Real Estate Small Business The Better Work Project Personal Finance Tech Science AI Enterprise Transportation Startups Innovation Markets Stocks Indices Commodities Crypto Currencies ETFs Lifestyle Entertainment Culture Travel Food Health Education Parenting Military & Defense Politics Reviews Home Kitchen Style Streaming Pets Tech Deals Gifts Tickets Video Big Bu
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia™ Advisory Board | Christer Rosén LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, y
List of 1,887 Neurology Startups in United States & Market Trends (May 2026) - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Inves … lic Total Funding till date : $215M Investors : AbbVie , The Dementia Discovery Fund and 20 Other s Latest Funding Round : Series E, Jul 25, 2018 , $ ***** Tracxn Score : 74 /100 What is this? Competitors Rank : 1 of 738 Competitors 2 . Intra-Cellular Therapies Developer of therapeutics for psychiatric and neurologic diseases. The company’s product, ITI-007 is a novel first-in-class 5-HT2A antagonist, Dopamine receptor phosphoprotein modulator (DPPM) designed to treat multipl … iotech , International Biotechnology Trust and 6 Other s Latest Funding Round : Grant (prize money), Jul 01, 2014 , $ ***** Tracxn Score : 71 /100 What is this? Competitors Rank : 7 of 3,434 Competitors View full list of companies in this sector 3 . Alto Neuroscience AI-driven drug discovery platform for neurological diseases based on patients biomarkers. The company's platform measures patients biomarkers like EEG and wearable data, behavioral patterns, genetics, and other f … in Neurology in United States • AskBio Announces FDA Acceptance of AB-1009 IND Application for Pompe Disease GlobeNewswire • Jan 08, 2026 • AskBio • Saluda Medical Receives Regulatory Approval for EVA™ Sensing Technology in Europe and Australia PR Newswire • Jan 08, 2026 • Saluda Medical • FDA rejects Vanda's jet lag drug after years-long dispute and 'long-shot' review Endpoints • Jan 08, 2026 • Vanda Pharmaceuticals • Anavex Life Sciences Receives FDA Feedbac … ya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD) Business Wire • Jan 05, 2026 • Coya Therapeutics • MapLight Therapeutics Receives Fast Track Designation for Alzheimer’s Disease Psychosis GlobeNewswire • Jan 05, 2026 • MapLight • Vanda Pharm
Jupiter Neurosciences Appoints Fishman and Lal to Nugevia Advisory Board | David Shapiro posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or … �𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧: By Type: Original (Branded) Tablets Generic Tablets By Application: Hospitals & Clinics Pharmacies 𝐌𝐚𝐫𝐤𝐞𝐭 𝐓𝐫𝐞𝐧𝐝𝐬: Growth of generic drug penetration globally Increasing adoption of extended-release formulations Rising focus on patient compliance & symptom stability Expansion of neurology treatment infrastructure in Asia-Pacific 𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬: Roche Teva Pharmaceuticals Pharmaceutical Industries ratiopharm betaph … e, while Online Pharmacies is the fastest-growing segment with CAGR of 9.4%. By Application: Musculoskeletal led with 34.2% share, while Neuropathic is the fastest-growing segment with CAGR of 7.1%. 𝐑𝐞𝐠𝐢𝐨𝐧𝐚𝐥 𝐎𝐮𝐭𝐥𝐨𝐨𝐤: While North America leads due to advanced healthcare infrastructure and high consumption rates, Asia-Pacific is emerging as a lucrative market driven by rising healthcare investments and growing adoption of modern therapeutics. 𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐏𝐫�
Jupiter Neurosciences Highlights Upcoming Milestones in --> Accessibility: Skip TopNav Jupiter Neurosciences Highlights Upcoming Milestones in Shareholder Letter April 08, 2025 08:00 ET | Source: Jupiter Neurosciences, Inc. Jupiter Neurosciences, Inc. Strategic expansion into longevity market creates near-term commercial opportunity alongside continued clinical advancement of JOTROL ™ JOTROL ™ development programs remain tariff-exempt; consumer longevity line on track with negligible cost exposure Jupiter, Florida, April 08, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: … e entry into those markets. Domestically, we’ve applied for a $16.5 million NIH grant to support a Phase II trial in MCI/early Alzheimer’s. If successful, this grant would fund a three-year trial beginning in late 2025. Entering the Longevity Market: A Natural Extension In March 2025, we unveiled a major strategic initiative — a partnership with Aquanova to launch a consumer-focused longevity and wellness product line under a wholly owned subsidiary. The first three SKUs, lau
Jupiter Neurosciences grants 600K options; Silva named COO | JUNS Prospectus Summary --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Cry … al base salary was increased to $340,200 . The Board approved a one-time option grant to Ms. Silva for up to 600,000 shares , director option grants of up to 100,000 shares each, discretionary option grants listed for five executives (amounts shown in the filing), and an additional 200,000-share option grant to Mr. Elmasri. Option grants vest over three years beginning September 2, 2026 in equal quarterly installments, with exercise prices set at the closing market price on t … terly installments, with exercise prices set at the closing market price on the grant dates. The prospectus supplement attaches the Form 8-K and the amendment to Ms. Silva’s employment agreement. Positive None. Negative None. Insights Compensation & Governance Analyst neutral Board approved executive promotion, salary bump, and sizable option grants. The Board appointed Alison Silva as Chief Operating Officer and President and raised her base salary to $340,200 . The Boar … to $340,200 . The Board also approved option awards including a 600,000 -share grant to Ms. Silva and director grants of 100,000 shares each, among other discretionary option grants. These option grants vest over three years commencing September 2, 2026 in equal quarterly installments. The exercise price for grants is set equal to the closing Nasdaq price on grant dates. Subsequent filings will show exact grant dates and exercise prices for each award. Key Figures Base Salar … igures Base Salary (Silva): $340,200 Prior Base Salary (Silva): $315,000 Option Grant (Silva): 600,000 shares +4 more 7 metrics Base Salary (Silva) $340,200 annual base salary effective June 5, 2026 Prior Base Salary (Silva) $315,000 previous annual base salary prior to amendment Option Grant (Silva) 600,000 shares one-time option grant under 202
LvlUp Marketing Edge Accelerator March Cohort Announced | LvlUp Ventures posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you ag … and this transition suggests that major firms are sharpening their focus on the application layer, where AI products compete for user behavior, retention, and brand power. The strategic implication is bigger than one partner changing firms. AI investing is entering a new phase across software, media, education, creator tools, and digital productivity. Infrastructure remains critical, but the next wave of value creation may come from companies that package powerful models into … ups through Raindrop Digital. Because when you take lessons from healthcare and apply them to broader tech: You get products that: • Scale without breaking • Earn trust faster • Solve real problems, not vanity metrics And now with AI: What used to require enterprise resources is accessible to early-stage founders. That is the shift. If you can build in healthcare You can build anywhere. #RaindropDigital #AI #Tech #Startups …more 8 Like Comment Share Copy LinkedIn Facebook X T … million seed round is a strong vote of confidence in one of the most promising application areas of Generative AI — hyper-personalized consumer engagement. NudgeBee is building an AI-driven consumer engagement platform that combines smarter targeting, deeper personalization, and advanced AI capabilities to help businesses connect with their customers more effectively. In a world where consumer attention is increasingly fragmented and generic marketing is increasingly ineffec
Value Investor Insight Contact Us Home About VII Free Sample Content Subscribe Archive Issue Archive Bonus Archive The Art of Value Investing We're Sorry The page you have requested is not available at this time. Please try again later or contact customer service at [email protected]. We apologize for the inconvenience. At the core of Value Investor Insight is the philosophy of the true value investor: buy something only for less than its intrinsic worth. As Warren Buffett’s long-time partner Charles Munger puts it, “All intelligent investing is value investing.”
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Jupiter Neurosciences Names Visionary Entrepreneur and --> Accessibility: Skip TopNav Jupiter Neurosciences Names Visionary Entrepreneur and Biohacker Jean Fallacara as Third Nugevia™ Brand Ambassador September 15, 2025 08:00 ET | Source: Jupiter Neurosciences, Inc. Jupiter Neurosciences, Inc. Partnership strengthens Nugevia ™ launch bringing clinical and scientific integrity to the fast-growing longevity space Jupiter, Florida, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) today announced that Jean Fallacara, visionary entrepreneur, neuroscientist, and in
Jupiter Neurosciences appoints Alison Silva as COO and President, grants options to executives — TradingView News Search Products Community Markets Brokers More EN Get started News / TradingView / Jupiter Neurosciences appoints Alison Silva as COO and President, grants options to executives Jupiter Neurosciences appoints Alison Silva as COO and President, grants options to executives 1 min read JUNS Jupiter Neurosciences appointed Alison Silva as Chief Operating Officer and President and approved option grants and salary increase for Silva and option grants for multiple executives and director … icer Type of Change Appointed; employment amendment; compensation change Option grant (discretionary bonus) Option grant (discretionary bonus); additional one-time option grant Option grant (discretionary bonus) Option grant (discretionary bonus) Effective Date Amendment dated June 5, 2026; option grant approved June 2, 2026; vesting from Sept 2, 2026 Approved June 2, 2026; vesting from Sept 2, 2026 Approved June 2, 2026; one-time additional grant approved June 2, 2026; vesti … y bonus in lieu of cash and to recognize his contributions (additional one-time grant) To provide discretionary bonus in lieu of cash To provide discretionary bonus in lieu of cash Replacement Info Not disclosed Not disclosed Not disclosed Not disclosed Not disclosed Background Details Employment agreement amended (originally dated Sept 1, 2021); base salary increased to $340,200 from $315,000 N/A N/A N/A N/A Board/Committee Role Changes Not disclosed Not disclosed Not disclo
Jupiter Neurosciences Investor News: Rosen Law Firm Encourages Jupiter Neurosciences, Inc. Investors to Inquire About Securities Class Action Investigation – JUNS Deutsch español français italiano Nederlands Login Analysis Quotes Screeners News Guides Training Londinia Platform Post an Analysis Request an analysis AI Londinia analysis Londinia Opportunities All Trading Opportunities Europe Stocks U.S. Stocks FX/Indices Cryptocurrencies Technical analyses All technical analyses Stocks Indices Forex Commodities Cryptocurrencies Futures AI analyses Need technical analysis? Request an analysis fro … to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=59144 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. What is this about: Rosen Law Firm is investigating potential civil securities claims. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have compar
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Jupiter Neurosciences Announces Patient Enrollment Underway --> Accessibility: Skip TopNav Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s Disease May 27, 2026 07:30 ET | Source: Jupiter Neurosciences, Inc. Jupiter Neurosciences, Inc. Investigational Oral Candidate JOTROL ™ Addresses a Parkinson’s Disease Market with No Current Disease-modifying Therapies Available Jupiter, FL, May 27, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage biopharmaceutical company developing investigational therapies for
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
JUPITER NEUROSCIENCES (JUNS) Stock News, Page 2 | StockTitan --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks Oil & Gas Def … lion core economic financing terms unchanged. The amendment modifies timing and application mechanics only and adds no new pricing, resets, or commitments. Management says the change aligns capital timing with advancing its Phase II Parkinson’s program and scaling commercial sales of Nugevia (JOTROL resveratrol), which shows ~25% repeat purchases and ~3% returns. The company remains in compliance with its transaction documents. Rhea-AI Impact Rhea-AI Sentiment End-of-Day 0.02 … - 11/05/2025 08:30 AM News Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease Rhea-AI Summary Jupiter Neurosciences (NASDAQ:JUNS) announced that the FDA cleared its IND to initiate a Phase 2a clinical trial of JOTROL in Parkinson’s disease on November 5, 2025. The clearance enables enrollment for an exploratory Phase 2a study focused on safety and tolerability with secondary PK/PD and biomarke
Jupiter Neurosciences, Inc. 4 Filing | JUNS | CapEdge beta Capedge Homepage Search Log In Free Sign Up Home Industries Earnings IPOs Transcripts Investor Holdings Stock Splits Jupiter Neurosciences, Inc. (JUNS) Filings Financials Holdings Share Price Transcripts ETFs Insiders Institutional Shorts X(twitter) LinkedIn Company Jupiter Neurosciences, Inc. Form 4 Timestamp 9:00 PM Jun 4, 2026 Views 7 Create a free CapEdge Account Track your favorite companies Receive email alerts for new filings Personalized dashboard of news Access all data and search results Log In Sign Up Actions Go back Copy li
D. Boral Capital | D. Boral Capital Skip to content Menu Home About Us Divisions Investment Banking Capital Markets Wealth Management Research and Strategy Transactions News & Insights Conference Careers Contact Research Access Home About Us Divisions Investment Banking Capital Markets Wealth Management Research and Strategy Transactions News & Insights Conference Careers Contact Research Access Strategic Investment Banking for Growth-Focused Companies A relationship-driven global investment bank, D. Boral Capital specializes in providing tailored financial solutions and strategic ad … ts, Crypto Settlements, Account Setups, Expense Management, Risk Reporting, and Fund Accounting. Phil has also managed numerous service provider and third-party relationships, which has helped streamline processes and improve internal efficiencies. Phil holds a Bachelor’s degree in Business Administration from the Miami Herbert Business School at the University of Miami. Jared S. Merlin Chief Compliance Officer Jared S. Merlin has been the Chief Compliance Officer at D. Boral
D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq: JUNS) in Connection with its ~$2 Million Registered Direct Offering | D. Boral Capital Skip to content Menu Home About Us Divisions Investment Banking Capital Markets Wealth Management Research and Strategy Transactions News & Insights Conference Careers Contact Research Access Home About Us Divisions Investment Banking Capital Markets Wealth Management Research and Strategy Transactions News & Insights Conference Careers Contact Research Access D. Boral Capital Acted as Exclusive Placement Ag … ts, Crypto Settlements, Account Setups, Expense Management, Risk Reporting, and Fund Accounting. Phil has also managed numerous service provider and third-party relationships, which has helped streamline processes and improve internal efficiencies. Phil holds a Bachelor’s degree in Business Administration from the Miami Herbert Business School at the University of Miami. Jared S. Merlin Chief Compliance Officer Jared S. Merlin has been the Chief Compliance Officer at D. Boral
Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson’s Trial | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Jupiter Neurosciences Announces Pricing of $2.0 Million --> Accessibility: Skip TopNav Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering May 20, 2026 14:38 ET | Source: Jupiter Neurosciences, Inc. Jupiter Neurosciences, Inc. Jupiter, FL, May 20, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced it has entered into a securities purchase agreement for the purchase and sale of 7,142,858
Demos: UI Controls and Frameworks --> Demos: UI Controls and Frameworks | DevExpress Chat Now Cart My Downloads Free Trial Log In Products Products MULTI-PLATFORM PACKAGES Universal Subscription Our Best Value – includes over 600 UI Controls, our award-winning reporting platform, DevExpress Dashboard, the eXpressApp Framework, CodeRush for Visual Studio and more. DXperience Subscription Save Hundreds – includes DevExpress UI Controls for WinForms, Blazor, ASP.NET Core (MVC & Razor Pages), ASP.NET Web Forms, MVC 5, WPF, our award-winning reporting platform and CodeRush for Visual Studio. HIGHLI … cumentation Code Examples Demos Training Need help or require more information? Submit your support inquiries via the DevExpress Support Center for assistance. Blogs About Us About Us CONNECT WITH DEVEXPRESS Blogs Events, Meetups and Tradeshows LEARN MORE ABOUT DEVEXPRESS About Us Careers / Job Opportunities News User Comments and Case Studies Our Awards MVP Program Announcing DevExpress Universal v26.1 Developer Express Inc is proud to announce the immediate availability of … ad Download DevExpress WinForms demo applications from GitHub. Outlook-Inspired Application Build apps with the UI elements your customers have come to expect from the world's most popular software suite. Run Demo Dental Clinic Application Create a relatively modern UX – a user experience that can be applied to different industries with minimal changes. Run Demo Stock Market Trader Build WinForms applications that replicate the innovative navigation UI. Run Demo New HTML & … S markup. Run Demo Learn more about HTML & CSS Support Touch-Enabled Hybrid Application Build touch-friendly WinForms applications that meet the evolving needs of your enterprise. Run Demo Fluent Mail Client Application In this demo application we use our Fluent Design Form to replicate Microsoft Mail's UI. Run Demo Help Resources Documentation Online Training Examples Tutorial Videos Getting Started with the Grid Control Getting Started with the Ribbon Control Getting St … UI — Case Study by DataWerkes: Field Services Management Platform (TimeWerkes) Application Security — Documents Are Untrusted Input Application Security — Stronger Hashes and Safer Passwords WPF Demos With over 130 optimized UI controls and libraries, the DevExpress WPF Subscription , can help you create powerful and visually stunning business s
Jupiter Neurosciences prices $2.0M stock offering | JUNS 8-K Filing --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks Oil & … the registered direct offering structure. What lock-up or issuance restrictions apply after the Jupiter Neurosciences (JUNS) offering? Under the Securities Purchase Agreement, Jupiter Neurosciences agreed to certain restrictions on issuing or selling common stock or common stock equivalents for 30 days following the offering’s closing, limiting near-term additional equity issuance. Filing Exhibits & Attachments 9 documents Press Releases EX-99.1 EX-99.1 11.5 KB Agreements &am
Jupiter Neurosciences, Inc. Enters Agreement to Acquire U.S. Rights for ALA-002, Advancing Position in MDMA-Based Therapeutics Amid Regulatory Changes | Quiver Quantitative --> Skip to Main Content MEMORIAL DAY API SALE 50% off your first year of Quiver API ... Use Promo Code: MEM50 Quiver API --> × Get a Free Trial on Quiver Premium Today! Upgrade Now Upgrade × Get Email Alerts On JUNS Stock Enter your email to receive free breaking news alerts and insights related to JUNS. Sign Up Now (Free) Home Datasets Most Popular Politician Search Congress Trading 2026 Midterm Elections Dona … et-moving data, filings, and signals for JUNS in real time. Sign Up $JUNS Hedge Fund Activity We have seen 6 institutional investors add shares of $JUNS stock to their portfolio, and 8 decrease their positions in their most recent quarter. Here are some of the largest recent moves: VESTOR CAPITAL, LLC removed 970,314 shares (-99.9%) from their portfolio in Q4 2025, for an estimated $989,720 CITADEL ADVISORS LLC added 101,661 shares (+inf%) to their portfolio in Q1 2026, for a
Jupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Jupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science July 24, 2025 | 6 min read Twitter LinkedIn Facebook Email Print Transforming a promising molecule into a clinically viable therapeutic platform Jupiter, … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing D … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease November 6, 2025 | 5 min read Twitter LinkedIn Facebook Email Print Jupiter, Florida, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinica … od and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 2a clinical trial of JOTROL ™ in patients with Parkinson’s disease. The FDA’s clearance marks a significant regulatory milestone for Jupiter, enabling the Company to begin enrollment in its exploratory Phase 2a trial designed to evaluate the safety and tolerability of JOTROL in patients with Parkinson’s, with secondary and exploratory endpoints to assess pharmacokin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Jupiter Orphan Therapeutics, Inc. Announces New Corporate Name, Jupiter Neurosciences, Inc. - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene The … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Jupiter Orphan Therapeutics, Inc. Announces New Corporate Name, Jupiter Neurosciences, Inc. September 14, 2021 | 3 min read Twitter LinkedIn Facebook Email Print Jupiter Orphan Therapeutics, Inc., a clinical stage pharmaceutical company focused on treating central nervous system (CNS) disorders and rare diseases, today … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Ce … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s Disease May 27, 2026 | 7 min read Twitter LinkedIn Facebook Email Print Investigational Oral Candidate JOTROL ™ Addresses a Parkinson’s Disease Market with No Current Disease-modifying Therapies Available Ju … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones February 5, 2025 | 5 min read Twitter LinkedIn Facebook Email Print Jupiter, Florida, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Comp … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Canc … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering May 20, 2026 | 3 min read Twitter LinkedIn Facebook Email Print Jupiter, FL, May 20, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical compa … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Jupiter Neurosciences Announces Strategic Focus on NLRP3 Pathway in Future JOTROL™ Trials - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Thera … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Jupiter Neurosciences Announces Strategic Focus on NLRP3 Pathway in Future JOTROL™ Trials January 14, 2025 | 6 min read Twitter LinkedIn Facebook Email Print Jupiter, Florida, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharma … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
OTC Markets | Official site of OTCQX, OTCQB, OTCID and Pink Limited Markets You need to enable JavaScript to run this app.
Jupiter Neurosciences, Inc. Announces Completion of Phase I Safety Trial with Enhanced Resveratrol Product, JOTROL™ - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Jupiter Neurosciences, Inc. Announces Completion of Phase I Safety Trial with Enhanced Resveratrol Product, JOTROL™ February 23, 2022 | 4 min read Twitter LinkedIn Facebook Email Print Jupiter Neurosciences, Inc. (“Jupiter” or the “Company”), today announced the completion of its Phas … al clinical trials, meeting performance objectives. The study was financed by a grant from the National Institute on Aging (NIA), entitled Safety and Pharmacokinetics of JOTROL for Alzheimer's Disease. "These data are exciting to report as we continue the advancement of our proprietary JOTROL™," stated Marshall Hayward , Ph.D., co-founder and CSO of Jupiter Neurosciences. "We believe that resveratrol has strong therapeutic potential but also shows poor bioavailability, which … ral indications and the FDA has accepted a first investigational new drug (IND) application of JOTROL™. More information may be found on the Company's website www.jupiterneurosciences.com . Forward-Looking Statements This press release may contain certain statements relating to future results which are forward-looking statements. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Jupiter Neurosciences, Inc. Announces Appointment of New Chief Financial Officer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Jupiter Neurosciences, Inc. Announces Appointment of New Chief Financial Officer January 12, 2023 | 5 min read Twitter LinkedIn Facebook Email Print Jupiter Neurosciences, Inc. today announced that it has appointed Saleem Elmasri, CPA, as new Chief Financial Officer, effective January 1, 2023 … eratrol administered in historical clinical trials. The study was financed by a grant from the National Institute on Aging (NIA), entitled Safety and Pharmacokinetics of JOTROL for Alzheimer's Disease. Resveratrol has the ability to cross the blood-brain barrier and has demonstrated positive effects on oxidative stress, inflammation and mitochondrial function in Friedreich's ataxia (FA) and Alzheimer's disease (AD) patients. About Jupiter Neurosciences, Inc. Jupiter Neuroscie … ral indications and the FDA has accepted a first investigational new drug (IND) application of JOTROL™. More information may be found on the Company's website www.jupiterneurosciences.com . Forward-Looking Statements This press release may contain certain statements relating to future results which are forward-looking statements. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Jupiter Neurosciences, Inc. Announces Research Breakthrough with JOTROL™ in Parkinson's Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown Jupiter Neurosciences, Inc. Announces Research Breakthrough with JOTROL™ in Parkinson’s Disease February 27, 2023 | 4 min read Twitter LinkedIn Facebook Email Print Jupiter Neurosciences, Inc. (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline focused on the treatment of … stered in historical clinical trials. These clinical studies were financed by a grant from the National Institute on Aging (NIA), entitled Safety and Pharmacokinetics of JOTROL for Alzheimer's Disease. Resveratrol has the ability to cross the blood-brain barrier and has demonstrated positive effects on oxidative stress, inflammation and mitochondrial function in Friedreich's ataxia (FRDA) and Alzheimer's disease (AD) patients. About Jupiter Neurosciences, Inc. Jupiter Neurosc … ral indications and the FDA has accepted a first investigational new drug (IND) application of JOTROL™. More information may be found on the Company's website www.jupiterneurosciences.com . Forward-Looking Statements This press release may contain certain statements relating to future results which are forward-looking statements. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Jupiter Neurosciences, Inc. Announces Journal of Alzheimer's Disease Publication Highlighting use of JOTROL™ - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Tr … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown Jupiter Neurosciences, Inc. Announces Journal of Alzheimer’s Disease Publication Highlighting use of JOTROL™ June 14, 2022 | 3 min read Twitter LinkedIn Facebook Email Print Pre-clinical proof-of-concept demonstrated in a disease model. Pre-clinical proof-of-concept demonstrated in a disease model JUPITE … eratrol administered in historical clinical trials. The study was financed by a grant from the National Institute on Aging (NIA), entitled Safety and Pharmacokinetics of JOTROL for Alzheimer's Disease. Resveratrol can cross the blood-brain barrier and has demonstrated positive effects on oxidative stress, inflammation, and mitochondrial function in Friedreich's ataxia (FA) and Alzheimer's disease (AD) patients. About Jupiter Neurosciences, Inc. Jupiter Neurosciences, Inc. is … ral indications and the FDA has accepted a first investigational new drug (IND) application of JOTROL™. More information may be found on the Company's website www.jupiterneurosciences.com . Forward-Looking Statements This press release may contain certain statements relating to future results which are forward-looking statements. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
+1- 800- RED-CHIP (733-2447) Toggle navigation Discovering Tomorrow's Blue Chips Today™ HOME ABOUT US Client Referrals Overview Team The RedChip Way Why CEO's Hire RedChip Case Studies In the News Careers SERVICES Value Proposition Investor Relations Digital IR TV and Media Education Newsletter Go Public CEO Interviews STOCKS EVENTS NEWSLETTER PODCASTS REDCHIP REVIEW CONTACT LOGIN Jupiter Neurosciences, Inc. (NASDAQ: JUNS) Stock Information | RedChip Jupiter Neurosciences, Inc. Investor Webinar January 6, 2026 Register Now! Jupiter Neurosciences, Inc. Investor Webinar January 6, 20
Jupiter Neurosciences (JUNS): … ‑ WTR Healthcare Happenings ‑ Apple Podcasts Rechercher Accueil Nouveautés Classements Rechercher 17 juin 23 min Jupiter Neurosciences (JUNS): Jotrol’s Bioavailability Breakthrough and the Key Parkinson’s Phase 2A Readout WTR Healthcare Happenings Lire In this episode, Christer Rosen, Founder and CEO of Jupiter Neurosciences (Nasdaq: JUNS), and President & COO Alison Silva join Water Tower Research’s Tim Gerdeman and Healthcare Analyst Robert Sassoon to discuss Jotrol, the company’s proprietary micellar formulation of resveratrol engineered to overcome long‑
Exploring Alzheimer’s, Parkinson’s, and Brain Health Solutions with Christer Rosén of Jupiter Neurosciences, Inc. <img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=8386908&amp;fmt=gif"> Skip to the main content. Approach Services About Insights Events Contact Login WEALTH PERSONALITY QUIZ Toggle Menu Toggle Menu WEALTH PERSONALITY QUIZ Approach Services About Insights Events Contact Login Linkedin True Wealth Assessment Everyone has their own unique relationship with money. Take this quiz to uncover the unconscious beliefs and emotio
JUNS Stock Quote Price and Forecast | CNN CNN values your feedback 1. How relevant is this ad to you? 2. Did you encounter any technical issues? Video player was slow to load content Video content never loaded Ad froze or did not finish loading Video content did not start after ad Audio on ad was too loud Other issues Ad never loaded Ad prevented/slowed the page from loading Content moved around while ad loaded Ad was repetitive to ads I've seen previously Other issues Cancel Submit Thank You! Your effort and contribution in providing this feedback is much appreciated. Close Ad Feedback C … file Nov 05, 2025 8:30am ET Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease by GlobeNewswire Oct 27, 2025 8:30am ET Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing by GlobeNewswire Sep 15, 2025 8:00am ET Jupiter Neurosciences Names Visionary Entrepreneur and Biohacker Jean Fallacara as Third Nugevia™ Brand Ambassador by GlobeNewswire Aug 26, 2025 8:00
+1- 800- RED-CHIP (733-2447) Toggle navigation Discovering Tomorrow's Blue Chips Today™ HOME ABOUT US Client Referrals Overview Team The RedChip Way Why CEO's Hire RedChip Case Studies In the News Careers SERVICES Value Proposition Investor Relations Digital IR TV and Media Education Newsletter Go Public CEO Interviews STOCKS EVENTS NEWSLETTER PODCASTS REDCHIP REVIEW CONTACT LOGIN Jupiter Neurosciences, Inc. (NASDAQ: JUNS) Stock Information | RedChip Jupiter Neurosciences, Inc. Investor Webinar January 6, 2026 Register Now! Jupiter Neurosciences, Inc. Investor Webinar January 6, 20
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
OTC Markets | Official site of OTCQX, OTCQB, OTCID and Pink Limited Markets You need to enable JavaScript to run this app.
Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Canc … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering May 22, 2026 | 4 min read Twitter LinkedIn Facebook Email Print Cash Runway Extended to Finance the Parkinson’s Program; Debt Paydown Improves Shareholder Equity Position Jupiter, FL, May 21, 2026 (GLOBE NEWSWIRE) -- … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Home Skip to main content Home News Politics Sports Things To Do Business Metro News Opinion Obituaries About Us eNewspaper Advertise with Us Archives Crosswords Comics Newsletters Connect With Us Iowa Caucuses Contributor Content Shopping USA 250 Ohio man missing since 1985 ID'd in Iowa cold case Crime & Courts Ohio man missing since 1985 ID'd as victim in Iowa cold case Crime & Courts Watch FedEx deliver Blank Park Zoo's new seal Des Moines Your package is delivered: FedEx gets harbor seal from LA to Iowa Des Moines See Blank Park Zoo's new seal arrive via FedEx Des Moines See which Iowa Sta
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Jupiter Neurosciences Licenses ALA-002 MDMA from PharmAla | Pienomial Home Platform Products KnolComposer KnolPersona KnolAI KnolForge Solutions Life Science Clinical Trial Intelligence Competitive Intelligence Financial Services Enterprise Intelligence Consulting Services Public Sector About Us Insights Book a Demo Home About Us Products KnolComposer KnolPersona KnolAI KnolForge Solutions Life Science Clinical Trial Intelligence Competitive Intelligence Financial Services Enterprise Intelligence Consulting Services Public Sector Platform Insights Mergers and Acquisitions Jupiter Neurosciences … in Islands, U.S. Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Message Submit 📍 Address One Research Ct, Suite 450 Rockville, MD 20850 ✉️ For General Inquiry [email protected] Related Posts 16 Oct 2025 Biocon Biologics and Civica Expand Partnership to Launch Insulin Glargine for U.S. Diabetes Patients Biocon Biologics and Civica expand their partnership to include Insulin Glargine, aiming to increase the availability of... 24 Apr 2026 Amneal inks $1.1B Kashiv buyou
Panama City News-Herald: Local News, Politics & Sports in Panama, FL Skip to main content Home News Sports Entertainment Lifestyle Military Opinion Business Obituaries Crosswords Comics eNewspaper For Subscribers Shopping Contributor Content Florida students show gains on FAST tests. How did your school do? Florida students showed gains in English and math scores under the new FAST testing system, Gov. DeSantis announced. How did your school do? Panama City shark victim faces long recovery. GoFundMe could help. Exchange of gunfire with FHP troopers leaves suspect hospitalized Crash on U.S. 231
Jupiter Neurosciences CEO to speak at Centri conference | JUNS Stock News --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks
Jupiter Neurosciences, Inc. (Nasdaq: JUNS) announced the company has entered into a term sheet to acquire exclusive, perpetual U.S. licensing rights to ALA-002, the lead drug candidate of PharmAla Biotech Holdings Inc. (CSE: MDMA; OTCQB: MDXXF). Under the term sheet, which the company describes as including up to $100 million in total potential consideration, Jupiter would make an upfront payment of $3.33 million, consisting of $1.5 million in cash and $1.83 million in JUNS common stock, with additional development milestone payments and single-digit royalties as the product is developed, appr
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Visalia/Tulare, CA - Home Skip to main content Home News Tulare Sports Entertainment Life Opinion Videos & Photos Obituaries Blogs eNewspaper Archives Crosswords Comics Newsletters For Subscribers Contributor Content New bakery Stuffed Buns opens near Fox Theatre Crystal Smith brings Texas roots to Visalia with the grand opening of her new kolache bakery Stuffed Buns. Should Tulare increase its city sales tax by a penny? Mission Oak's Eddie Bravo bounces back from injury to league MVP Planning a National Park trip? Swim spot near Visalia is America’s No. 1 local Where to watch Fourth of July f
Jupiter Neurosciences Secures $100M Term Sheet for --> Accessibility: Skip TopNav Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech May 20, 2026 07:38 ET | Source: Jupiter Neurosciences, Inc. Jupiter Neurosciences, Inc. Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order Accelerating Psychedelic Medicine JUPITER, FL, May 20, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter"
Redding - Home Skip to main content Home News Sports Business Opinion Entertainment Lifestyle Obituaries Media eNewspaper Crosswords Comics Newsletters For Subscribers Contributor Content Appeals court denies state request for expedited ruling on Measure B Proponents of the controversial election measure hailed the decision as a victory, while the state said the decision was only procedural. Shasta County judge upholds $106K in fines in land use dispute Redding business woman, 70, alleges police misconduct Yosemite removes entry reservations for 2026 travel Man wanted after duckling killing at
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
Jupiter Neurosciences, Inc. (NASDAQ: JUNS) Founder, Chairman and CEO Christer Rosén recently presented at the Second Annual Centri Capital Conference at Nasdaq MarketSite, hosted by Centri Business Consulting. In this clip, he walks investors through the structure of the company's lead clinical program. Jupiter Neurosciences is a B2i Digital Featured Company (https://b2idigital.com/jupiter-neurosciences-1) developing therapies and consumer wellness products built on its proprietary JOTROL micellar resveratrol delivery platform. For more information, visit https://www.jupiterneurosciences. … A successful readout opens the door to strategic partnership discussions or NIA grant funding for follow-on indications such as Alzheimer's and mild cognitive impairment. Watch the full presentation, courtesy of Centri Business Consulting: https://youtu.be/nN6XL3_Q8aI Jupiter Neurosciences is led by Christer Rosén, Founder, Chairman and CEO; Alison Silva, President and Chief Business Officer; Saleem Elmasri, CPA, Chief Financial Officer; and Marsh Hayward, Ph.D., Co-Foun
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Jupiter Neurosciences registers 16M shares for resale | JUNS IPO Registration (S-1) --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Cryp … t a Phase 2 Parkinson’s trial, expand direct‑to‑consumer Nugevia marketing, and fund general corporate purposes. Positive None. Negative None. Insights Capital structure and biotech financing analyst neutral Large resale registration tied to SEPA adds flexible funding but also notable dilution risk. Jupiter Neurosciences is registering up to $20.0M of equity capacity under a standby equity purchase agreement with Yorkville, including 16,000,000 Advance Shares for resale. Issu … dditional gross proceeds, initially applied to repay Convertible Notes, then to fund a Phase 2 Parkinson’s trial, Nugevia marketing, and general corporate purposes. See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google Add on Google Not now S-1 Filings Explained: Reading an IPO Registration → Available on EDGAR 06/26/2026 - 04:34 PM Accepted by SEC EDGAR 06/26/2026 - 04:33 PM Learn about SEC filing dates ⛶ F … opment timeline (including targeted dates for Phase 3 completion and a New Drug Application in the United States, subject to customary terms and conditions for licensing transactions of this nature) and customary interim operating covenants for PharmAla from signing to closing, including maintenance of the Assets and preservation of related rights. The Term Sheet expressly provides that, other than certain binding provisions (including, among others, escrow, fees and e … ffered for resale pursuant to this prospectus. (4) Yorkville is a fund managed by Yorkville Advisors Global, LP (“Yorkville LP”). Yorkville Advisors Global II, LLC (“Yorkville LLC”) is the general partner of Yorkville LP. All investment decisions for Yorkville are made by Yorkville LLC’s President and m
Lubbock Avalanche-Journal: Local News, Politics & Sports in Lubbock, TX Skip to main content Home News Sports Entertainment Lifestyle Opinion Business Obituaries Crosswords Comics eNewspaper For Subscribers Shopping Contributor Content United Family stores, Sartori Cheese partner for Make-A-Wish campaign Now through Aug. 4, The United Family and Sartori Cheese are partnering to support Make-A-Wish. Here's how shoppers in West Texas, NM can help. Jones Stadium field-storm song lands TTU student in a trademark suit What Texas Tech basketball's Donovan Atwell brings to Chicago Bulls Texas logs it … U.S. under heat dome weather South Plains College receives $2M Moody Foundation grant education Help Terms of Service Subscription Terms & Conditions Privacy Policy Site Map Accessibility Our Ethical Principles Responsible Disclosure Your Privacy Choices © Copyright Gannett 2026
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Times-Mail | Local News, Politics & Sports in Bedford, IN Skip to main content Home News Sports Life Entertainment Opinion Business Obituaries Crosswords Comics eNewspaper For Subscribers Shopping Contributor Content Experts offer tips to help veterans with PTSD on July 4 news 5 ways to keep your pets calm during Fourth of July fireworks news These iconic Midwest sites helped shape the United States Experience Mega Millions winning numbers for Friday, June 26, 2026 lottery Indiana football's Josh Hoover enjoys working with 'demanding' Tino Sunseri IU Sure, abolish property taxes for seniors —
D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering | Newswire You are using an outdated browser. Please upgrade your browser or activate Google Chrome Frame to improve your experience. Products Press Release Distribution Press Release Optimizer Media Suite Media Database Media Pitching Media Monitoring Analytics Media Room Pricing Customer Stories Resources Education Blog PR & Earned Media Planner For Journalists RSS Feeds Support Newsroom Log In Sign Up Back to Media Room D. Boral Capit
Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Ce … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago February 25, 2026 | 2 min read Twitter LinkedIn Facebook Email Print Jupiter Neurosciences, Inc. Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a- … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace is the digital hub for life science news and jobs. We provide essential insights, o … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Jupiter Neurosciences, Inc. (Nasdaq: JUNS) announced the company has entered into a term sheet to acquire exclusive, perpetual U.S. licensing rights to ALA-002, the lead drug candidate of PharmAla… | David Shapiro LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at a
Galesburg Register Mail: Local News, Politics & Sports in Galesburg, IL Skip to main content Home News Sports Entertainment Lifestyle Opinion Business Obituaries Crosswords Comics eNewspaper For Subscribers Contributor Content A reminder of what fireworks are legal and illegal in Illinois Illinois limits fireworks to approved items and novelty effects. Here’s what state law allows and what’s prohibited this summer. Eddie Vedder gifts young Midwest musician a guitar from his collection On the market: Galesburg home with gourmet kitchen lists for $385K Experts offer tips to help veterans with PT
Jupiter Neurosciences, Inc. to Present at Centri Capital Conference on April 14 Paramètres des fichiers témoins Nous utilisons des fichiers témoins pour analyser le comportement des internautes afin d’assurer l’amélioration continue du site Web. Consultez notre Politique de protection des renseignements personnels et nos Conditions d'utilisation . Nécessaires Analyse de données Tout accepter Accepter la sélection Tout refuser × Passer au contenu principal Newsfile Recherche Anglais Français Allemand Espagnol Recherche × Ouvrir une session Nom d’utilisateur Mot de passe Ouvrir une session Newsf … ce on April 14 2026-04-13 9:00 AM EDT Profil de société Aug 22, 2025 EDGAR Next Deadline Guide: Your Final Checklist " The EDGAR Next deadline is no longer a future concern—it is an immediate compliance requirement. Companies that fail to complete enrollment risk losing filing access at a critical time. " The EDGAR Next deadline is only weeks away. On September 15, 2025, the SEC will switch to its new system, and companies that haven’t completed enrollment risk being unable t
blueridgenow.com: Local News, Politics & Sports in Hendersonville, NC Skip to main content Home News Sports Entertainment Lifestyle Opinion Business Obituaries Crosswords Comics eNewspaper For Subscribers Contributor Content Jabil announces $102M expansion, to create 148 jobs in Flat Rock After Hendersonville and Henderson County announced up to $6.5M in incentives, medical device factory Jabil plans to expand in East Flat Rock. Five bold predictions for Mountain 8 Conference football in 2026 Henderson County volunteers honored with statewide award Tick bites have risen in the southeast in 202 … ed hearing local Montgomery Sky Farm sells out dinners after chef's James Beard Award win life Nolichucky River access re-opens after Hurricane Helene local RiverLink gets grant to grow river cane at scale for Helene recovery local NC Lottery Powerball, Pick 3 Day results for June 24, 2026 local Help Terms of Service Subscription Terms & Conditions Privacy Policy Site Map Accessibility Our Ethical Principles Responsible Disclosure Your Privacy Choices © Copyright Gannett 2026
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Pipeline - Jupiter Neurosciences, Inc Home Company Investors JOTROL™ Pipeline Contact PIPELINE Jupiter Neurosciences has developed the first and only resveratrol product that safely reaches therapeutic levels without GI-side effects creating treatment possibilities in many indications. Our platform product JOTROL™ is being studied as an oral medication for Alzheimer’s disease and for people with rare diseases. --> PIPELINE Development Strategy: One Phase I study enabling 3 rare diseases and MCI starting directly in Phase II Results from the Phase I pharmacokinetics study will be cross-referenc
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Christer Rosén - Founder, Chairman & CEO at Jupiter Orphan Therapeutics | The Org Platform Enrich Pricing Log in Sign up Jupiter Orphan Therapeutics Christer Rosén Unverified Christer Rosén Founder, Chairman & CEO Contact Originally from Halmstad, Sweden, Christer Rosén is the primary founder and Chairman & CEO of Jupiter Neurosciences, Inc.. His background and education as a programmer and system analyst gives him a solution minded mentality and an expert in building companies with strong and dedicated people. He started his first company at the age of 17, a discotheque opened o
Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Jupiter Neurosciences, Inc. to Present at The Market Movers Investor Summit Cookie Settings We use cookies to analyze user behavior in order to constantly improve the website for you. View our Privacy Policy and Terms of Use . Necessary Analytics Accept All Accept Selection Reject All × Skip to main content Newsfile Search English Français Deutsch Español Search × Login Username Password Login Newsfile Login Search Français Home About About Company Overview Who We Serve Upcoming Events Careers Services Services Press Release Distribution News Service Overview Global Distribution Additional New … eatures fireside chats with Alex Rodriguez, Chairman and CEO of A-Rod Corp, and Grant Cardone, CEO of Cardone Capital, in addition to company presentations and one-on-one meetings throughout the day. Event Details: Summit Dates: May 5, 2026 Company Presentation: Tuesday, May 5, 2026 Time: 09:00 AM ET Location: 48 Wall Street, New York, NY (The original Bank of New York) Request an invitation to attend at www.marketmoverssummit.com . Summary of Market Movers Investor Summit Th … g on May 5th. The summit brings together public and private company executives, fund managers, and family offices for a focused, high-caliber experience. The agenda includes company presentations, exclusive fireside chats and keynote sessions, a pop-up lunch from the legendary Katz Delicatessen and a surprise musical guest. About Jupiter Neurosciences, Inc. Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammat
Jupiter Neurosciences, Inc. (NASDAQ: JUNS) Founder, Chairman and CEO Christer Rosén recently present | How to get rid of a cold fast, How to quickly get rid of colds, Consulting business Skip to content Explore When autocomplete results are available use up and down arrows to review and enter to select. Touch device users, explore by touch or with swipe gestures. Log in Sign up
Jupiter Neurosciences, Inc. (NASDAQ: JUNS) Founder, Chairman and CEO Christer Rosén recently presented at the Second Annual Centri Capital Conference at Nasdaq MarketSite, hosted by Centri Business Consulting. In this clip, he addresses the commercial opportunity behind the Nugevia consumer product line. Jupiter Neurosciences is a B2i Digital Featured Company (https://b2idigital.com/jupiter-neurosciences-1) developing therapies and consumer wellness products built on its proprietary JOTROL micellar resveratrol delivery platform. For more information, visit https://www.jupiterneurosciences.com
Jupiter Neurosciences CEO Christer Rosén on Nugevia Commercial Opportunity | David Shapiro posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join … y Business Journal Innovator of the Year 2025 🏆 AbbVie Allergan ULP Innovation Award Winner December 2023 We are focused on advancing bioelectric regenerative medicine, precision protein expression technologies, longevity science, muscle and cognitive health optimization, and next-generation regenerative platforms designed to improve healthspan. This is not a trend for us. It is four plus decades of work. Trusted by the doctors who wrote the standards. 🌐 www.LionheartLongev
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
false 0001679628 DEF 14A 0001679628 2024-01-01 2024-12-31 0001679628 2023-11-30 2024-01-01 2024-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       SCHEDULE 14A       Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934   Filed by the Registrant ☒   Filed by a Party other than the Registrant ☐   Check the appropriate box:   ☐ Preliminary Proxy Statement   ☐ Confidential, for U … ormat on December 19, 2025 at 10:00 a.m. Eastern Time. You may attend, vote and submit questions during the Annual Meeting via the Internet at https://meetings.lumiconnect.com/200-142-773-960 . We have designed the format of the Annual Meeting to ensure that you are afforded the same rights and opportunities to participate as you would at an in-person meeting, using online tools to ensure your access and participation.   The Notice of the Annual Meeting and Proxy Stateme … ormat on December 19, 2025 at 10:00 a.m. Eastern Time. You may attend, vote and submit questions during the Annual Meeting via the Internet at https://meetings.lumiconnect.com/200-142-773-960 . We have designed the format of the Annual Meeting to ensure that you are afforded the same rights and opportunities to participate as you would at an in-person meeting, using online tools to ensure your access and participation.   The purpose of the Annual Meeting is to consider a … SCIENCES, INC . 1 QUESTIONS AND ANSWERS ABOUT THIS PROXY STATEMENT AND VOTING 2 PROPOSAL NO. 1: ELECTION OF DIRECTORS 10 EXECUTIVE OFFICERS 18 EXECUTIVE COMPENSATION 19 PROPOSAL NO. 2: INCREASE IN AUTHORIZED SHARES OF COMMON STOCK 34 PROPOSAL NO. 3: ADOPTION OF JUPITER NEUROSCIENCES, INC. 2025 EQUITY INCENTIVE PLAN 35 PROPOSAL NO. 4: RATIFICATION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 42 PROPOSAL NO. 5: ISSUANCE OF SHARES PURSUANT TO NASDAQ LISTING RULES 5635(B) AND … . 5: ISSUANCE OF SHARES PURSUANT TO NASDAQ LISTING RULES 5635(B) AND 5635(D) 43 PROPOSAL NO. 6: ADJOURNMENT 48 SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS. 49 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 52 OTHER MATTERS 54 HOUSEHOLDING 54 ANNEX A - CERTIFICATE OF AMENDMENT TO THE CERTIFI
Instagram Instagram Log In Sign Up Close Never miss a post from dboralcapital Sign up for Instagram to stay in the loop. Sign up Log in dboralcapital • Follow More options dboralcapital 4w D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq: JUNS) in Connection with its ~$2 Million Registered Direct Offering. We would like to thank the Issuer, Jupiter Neurosciences, Inc., Chief Executive Officer, Christer Rosén, Chief Financial Officer, Saleem Elmasri, President and Chief Business Officer, Alison Silva, Chief Administrative Officer, Alexander Rosén, Issue
Jupiter Neurosciences Enrolls Patients in JOTROL Phase 2a for Parkinson's Disease | Pienomial Home Platform Products KnolComposer KnolPersona KnolAI KnolForge Solutions Life Science Clinical Trial Intelligence Competitive Intelligence Financial Services Enterprise Intelligence Consulting Services Public Sector About Us Insights Book a Demo Home About Us Products KnolComposer KnolPersona KnolAI KnolForge Solutions Life Science Clinical Trial Intelligence Competitive Intelligence Financial Services Enterprise Intelligence Consulting Services Public Sector Platform Insights Clinical Trial Up … in Islands, U.S. Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Message Submit 📍 Address One Research Ct, Suite 450 Rockville, MD 20850 ✉️ For General Inquiry [email protected] Related Posts 23 May 2025 Adagene Announces Positive Updated Data for Muzastotug (ADG126) in Combination with Pembrolizumab for Colorectal Cancer at ASCO Adagene announced updated Phase 1b/2 data for its anti-CTLA-4 antibody, Muzastotug (ADG126), in combination with pembrol... 23 Jul 2025 Abi
🚀 Jupiter Neurosciences (Nasdaq:... - RedChip Companies, Inc. Facebook Log In RedChip Companies, Inc.'s Post RedChip Companies, Inc. Verified account June 9, 2025 · Shared with Public Jupiter Neurosciences ( Nasdaq : JUNS) Enters Consumer Market with Nugevia™ Launch Jupiter has officially unveiled Nugevia™, a premium longevity and performance supplement line powered by its proprietary JOTROL™ technology-offering 9x bioavailability over traditional resveratrol. Why This Matters to Investors: - Near-Term Revenue Catalyst: First consumer products launch in Q3 2025, creating an immediate mon
Jupiter Neurosciences, Inc. Announces Journal of Alzheimer's Disease Publication Highlighting use of JOTROL | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...